Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403

NCT00655824 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
124
Enrollment
INDUSTRY
Sponsor class

Stopped The clinical development of intravenously administered ofatumumab in RA will no longer be pursued, so this study was prematurely terminated by the Sponsor.

Conditions

Interventions

Sponsor

GlaxoSmithKline